<DOC>
	<DOCNO>NCT02091245</DOCNO>
	<brief_summary>This research study involve participant acute lymphoblastic acute myelogenous leukemia relapse become resistant ( refractory ) standard therapy . This research study evaluate drug call KPT-330 . Laboratory study suggest study drug , KPT-330 , may prevent leukemia cell grow may lead destruction leukemia cell . It think KPT-330 activates cellular process increase death leukemia cell . The main goal study evaluate side effect KPT-330 administer child adolescent relapse refractory leukemia .</brief_summary>
	<brief_title>Phase I Trial Selective Inhibitor Nuclear Export , KPT-330 , Relapsed Childhood ALL AML</brief_title>
	<detailed_description>The investigator try determine safe dose KPT-330 give participant different dose level study drug . Three six participant receive start dose drug . If side effect severe , next group participant take study drug high dose level . Up 3 dose level study drug test , participant assign dose level , participant always receive dose . The high dose people give safely call maximum tolerate dose ( MTD ) . Once MTD determine , 10 additional participant receive dose study drug . Participants age ≥18 month ( 540 day ) ≤ 21 year relapse ( second subsequent relapse ) refractory ALL AML eligible enroll . KPT-330 administer twice week Days 1 3 four week ( cycle 4 week ) . All participant receive intrathecal chemotherapy Day 1 cycle . Participants CNS-2 disease receive additional dos IT chemo . Pharmacokinetic ( PK ) sample collect Cycle 1 Days 1-3 15 . PK sample collect Cycle 2 Day 15 . Pharmacodynamic ( PD ) sample collect Cycle 1 Days 1-3 . PD sample collect Cycle 2 Day 15 . Additional optional correlative biology sample collect . Participants monitor closely adverse event . Participants physical exam blood work week cycle .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<criteria>Age : Patient must ≥ 18 month ( 540 day ) ≤ 21 year . Histologically confirm diagnosis relapse refractory ALL ( include Burkitt leukemia ) , AML , mixed lineage leukemia , biphenotypic leukemia , chronic myelogenous leukemia ( CML ) blast crisis . Refractory disease define : Persistent disease least two induction cycle . Relapsed disease : Second subsequent relapse , relapse refractory salvage chemotherapy Patients must bone marrow ≥ 5 % blast ( M2 M3 marrow ) either aspirate biopsy sample , assess morphology flow cytometry . Patients CNS 1 CNS 2 disease eligible . Patients isolated CNS relapse CNS 3 disease eligible . Please refer Section 11.1.3 definition CNS disease status interpretation traumatic lumbar puncture . Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study meet follow criterion : Myelosuppressive chemotherapy : 14 day must elapse since completion myelosuppressive therapy . Individuals may receive follow medication within 14 day without `` washout '' period : Standard maintenance therapy ( vincristine , 6MP , corticosteroid , low dose methotrexate ) Hydroxyurea Intrathecal chemotherapy methotrexate , hydrocortisone and/or cytarabine . Radiation therapy ( XRT ) : Total Body Irradiation ( TBI ) craniospinal radiation therapy : Must complete 90 day study entry Palliative XRT : XRT chloromas require washout period . Biologic ( antineoplastic agent ) : At least 7 day last dose biologic agent . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair . Immunotherapy : At least 6 week completion type immunotherapy , e.g . tumor vaccine . Monoclonal antibody : At least 3 halflives antibody last dose monoclonal antibody . ( See table DVL homepage list monoclonal antibody halflives : http : //members.childrensoncologygroup . Performance status : Lansky ≥ 50 individual 18 month ≤ 16 year old ; Karnofsky &gt; 50 % individual 1721 year old ( See Appendix I ) . Adequate organ function define follow : Direct bilirubin ≤1.5 X institutional upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) ≤ 3X institutional ULN Creatinine institutional ULN creatinine clearance ≥ 60 mL/min/1.73 m2 subject creatinine level institutional normal Echocardiogram must shorten fraction ejection fraction great institutional low limit normal age gender . Female patient childbearing potential must negative urine serum pregnancy test confirm prior enrollment . Female patient infant must agree breastfeed infant study . The effect KPT330 develop human fetus unknown . For reason many chemotherapeutic agent know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability participant ( parent/guardian participant minor ) understand willingness sign write informed consent document . Participants exhibit follow condition screen eligible admission study . Inability take tolerate enteral medication Individuals CNS 3 leukemia Individuals Down syndrome Patients prior hematopoietic stem cell transplant ( HSCT ) eligible , exception following : Autologous HSCT within 60 day study entry Allogeneic HSCT within 90 day study entry Evidence graftversushostdisease ( GVHD ) Treatment immunosuppressive medication within 14 day ; however , wean stable dos steroid ( must ≤ 20 mg/m2/day prednisone equivalent ) and/or calcineurin inhibitor permit . Treatment hematopoietic growth factor ( GCSF ) : Longacting ( e.g. , Neulasta ) within 14 day prior study entry Shortacting ( e.g. , Neupogen ) within 7 day prior study entry Treatment investigational agent within 28 day study entry , 3 halflives , whichever longer . Patients exclude plan administer nonprotocol chemotherapy , radiation therapy , immunotherapy study period . Any ECG abnormality opinion principal investigator would preclude safe participation study Patients refractory red blood cell platelet transfusion . Patients receive anticoagulation therapy eligible long anticoagulation regimen stable &gt; 1 month . Patients systemic fungal , bacterial , viral infection exhibit ongoing signs/symptoms related infection without improvement despite appropriate antibiotic treatment . For doseescalation cohort , know positivity human immunodeficiency virus ( HIV ) ; baseline test HIV require . HIV positive patient eligible doseexpansion cohort . Known active hepatitis A , B , C infection ; know positive HCV RNA HBsAg ( HBV surface antigen ) ; baseline test viral hepatitis require . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption KPT330 ( e.g . ulcerative colitis , uncontrolled nausea , vomit , diarrhea , malabsorption history small bowel resection ) Individuals significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Individuals history different malignancy ( acute leukemia ) ineligible except follow circumstance : Individuals eligible different malignancy complete remission time study entry . Pregnant woman exclude study KPT330 chemotherapeutic agent unknown teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother study agent , breastfeed allow study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsed acute lymphoblastic leukemia ( ALL )</keyword>
	<keyword>Refractory acute lymphoblastic leukemia ( ALL )</keyword>
	<keyword>Relapsed acute myelogenous leukemia ( AML )</keyword>
	<keyword>Refractory acute myelogenous leukemia ( AML )</keyword>
	<keyword>Relapsed childhood leukemia</keyword>
	<keyword>Relapsed mixed lineage leukemia</keyword>
	<keyword>Refractory mixed lineage leukemia</keyword>
	<keyword>Relapsed biphenotypic leukemia</keyword>
	<keyword>Refractory biphenotypic leukemia</keyword>
	<keyword>Chronic myelogenous leukemia ( CML ) blast crisis</keyword>
</DOC>